ArticleCancer medicine2026
Association of the PD-L1 CPS With the Efficacy of First-Line Nivolumab Plus Chemotherapy for Unresectable Advanced or Recurrent Gastric Cancer.
Article in Cancer medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe CheckMate 649 trial showed the superiority of first-line nivolumab plus chemotherapy (Nivo-CT) over chemotherapy alone for advanced gastric or gastroesophageal junction (GEJ) cancer with a programmed cell death-ligand 1 (PD-L1) combined positive score (CPS) ≥ 5. However, few studies have investigated the correlation between PD-L1 CPS and the efficacy of first-line Nivo-CT in the real-world setting.
methodsThis multicenter retrospective study included patients with unresectable advanced or recurrent gastric or GEJ cancer who were started on first-line Nivo-CT between December 2021 and December 2023 at any of four institutions in Japan. PD-L1 CPS was classified into three groups (< 1, 1 to < 5, and ≥ 5) before the start of Nivo-CT.
resultsA total of 234 patients were included (median age 70 years; 64.5% male; 89.7% with gastric primary). PD-L1 CPS was < 1 in 35 patients (15.0%), 1 to < 5 in 76 (32.5%), and ≥ 5 in 123 (52.5%). Median follow-up was 14.0 months (range 2.3-30.3). Median overall survival was 18.7 (95% confidence interval [CI] 17.4-not reached), 23.4 (95% CI 17.7-not reached), and 18.3 months (95% CI 13.3-22.5), with objective response rates of 30.8%, 66.7%, and 61.3%. Multivariate analysis did not identify PD-L1 CPS as a prognostic factor, whereas an Eastern Cooperative Oncology Group performance status ≥ 1, a GEJ primary, and two or more metastatic sites were associated with poor prognosis.
conclusionsThe PD-L1 CPS had no significant effect on prognosis in patients with unresectable advanced or recurrent gastric or GEJ cancer treated with first-line Nivo-CT.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.